ArticleMedical oncology (Northwood, London, England)2019

The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC).

Jakub Kucharz et al.PubMed ↗Publisher ↗

No numbers read from the abstract.